Research

Drug Companion Diagnostics

Checkpoint Inhibitor Melanoma Trial

Study Design:

  • Metastatic melanoma, BRAF mutant patients, treated with experimental checkpoint inhibitor drugs.

Results:

  • Stratified patients into 3 cohorts (responsive, non-responsive, toxic).


Autoantibody Biomarker Discovery

Systemic Lupus Erythematosus (SLE)

Study Design:

  • Identification of novel autoantibodies in SLE and stratification of subgroups of SLE individuals.

Results:

  • 4 SLE subgroups were categorised based on hierarchical clustering and principal component analysis (PCA) with known autoantigens such as TROVE2 (Ro60) and SSB (La) forming a single cluster and novel TGF-β signalling (SMAD2 and SMAD5) and TLR signalling (My88) autoantigens forming another cluster.


Protein Interaction Assays

DNA-Protein Interaction Study

Study Design:

  • p53 microarray printed onto a neutravidin-derivatised dextran hydrogel surface probed with Cy3-labelled GADD45 duplex oligo

Results:

  • Quantitative parallel thermodynamic analysis revealed previously unknown functional effects of mutation on p53 protein-DNA interaction

  • Differential DNA binding activity of p53 mutant proteins

  • Quantitative analysis unravels mechanistic differences between ‘loss of function’ mutations 

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X